Pacific Biosciences Releases New Software and Chemistry for Sequel System
August 04 2016 - 4:10PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB) today
announced it has released a set of key updates for the Sequel™
System, the company’s latest product based on its Single Molecule,
Real-Time (SMRT®) Sequencing technology. The new release provides
performance improvements via updated sequencing chemistry,
optimized sample clean-up protocols, and associated software that
together further improve read lengths, throughput and accuracy of
the system. In addition, as customers upgrade their Sequel Systems
to the new software and chemistry, they will no longer be subject
to the supply constraints for SMRT Cells that were in effect
earlier this year.
“These updates reinforce our continued commitment to improving
SMRT Sequencing throughput, read length, and accuracy through
optimized protocols and chemistry to enhance applications, such as
de novo assembly, targeted sequencing, and the Iso-Seq™ method for
RNA analysis,” said Kevin Corcoran, Senior Vice President of Market
Development for Pacific Biosciences. “With this release, we have
removed SMRT Cell supply constraints as we begin to source SMRT
Cells for the Sequel System from our high-volume supplier.”
Yi Han, Ph.D., Assistant Professor in the Department of
Molecular and Human Genetics at Baylor College of Medicine, who had
early access to the new chemistry and software commented: “We are
very impressed with the data we are getting with the latest update
to the Sequel chemistry, sample prep, and software. As one of the
first adopters of SMRT Sequencing, we appreciate how PacBio has
partnered with us since 2010 to continually make improvements to
the technology that directly benefit our research.”
Robert Sebra, Ph.D., Director of Technology Development &
Associate Professor of Genetics and Genomic Sciences at the Icahn
School of Medicine at Mount Sinai stated, "To date we’ve
successfully demonstrated high molecular depth targeted long-range
amplicon sequencing for a variety of medically relevant and other
research applications, in addition to using the Iso-Seq and variant
validation pipelines on Sequel. With the most recent
releases, we’ve now seen significantly improved sequencing metrics
and the non-restricted SMRT Cell supply will now enable larger
genomes to be sequenced, and research requiring extreme molecular
depth using the Sequel technology to truly differentiate the power
of higher throughput long-read single molecule sequencing."
More information about Sequel is available at:
http://www.pacb.com/products-and-services/pacbio-systems/sequel/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future availability, uses, quality or
performance of, or benefits of using, products or technologies, and
other future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.”Pacific
Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2024 to May 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From May 2023 to May 2024